Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines
- PMID: 1346236
- PMCID: PMC1886242
Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines
Abstract
In this communication, the authors summarize their characterization of eight ovarian adenocarcinoma-derived cell lines for level of neu gene amplification, expression of neu transcripts and protein, and intraperitoneal tumorigenicity in nude mice. Two of the eight cell lines in our study (SKOV3 and YAOVBIX1) exhibited five- to ninefold neu DNA sequence amplification, accompanied by up to 200-fold overexpression of transcripts and protein (p185). Both of these cell lines expressed a major approximately 7.5 kb neu-complementary transcript not previously reported in other neu-positive tumor cell lines. One pair of cell lines (YAOVBIX1 and YAOVBIX3), isolated from a single ovarian carcinoma patient's ascites sample differed dramatically in regard to level of neu gene amplification and expression. Immunohistochemical staining of the primary ovarian tumor from which these two lines were derived demonstrated populations of both neu-positive and neu-negative malignant epithelial cells. Seven of the eight ovarian carcinoma lines produced intra-abdominal tumors after intraperitoneal injection into nude mice, irrespective of level of neu gene expression. This study demonstrates tumor cell heterogeneity with regard to neu gene amplification and expression in an ovarian adenocarcinoma, reveals the overexpression of novel neu-complementary transcripts in two independently isolated ovarian adenocarcinoma cell lines, and suggests that neu gene expression is not required for intraperitoneal tumorigenicity of ovarian carcinoma xenografts in a nude mouse model system.
Similar articles
-
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.Cancer Res. 1993 Feb 15;53(4):891-8. Cancer Res. 1993. PMID: 8094034
-
Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer.Cancer Lett. 1992 Jan 10;61(2):95-103. doi: 10.1016/0304-3835(92)90166-s. Cancer Lett. 1992. PMID: 1346099
-
Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.Oncogene. 1990 Sep;5(9):1403-8. Oncogene. 1990. PMID: 1699198
-
HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.Am J Clin Pathol. 1999 Mar;111(3):311-6. doi: 10.1093/ajcp/111.3.311. Am J Clin Pathol. 1999. PMID: 10078105 Review.
-
Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.Eur J Obstet Gynecol Reprod Biol. 1997 Feb;71(2):173-9. doi: 10.1016/s0301-2115(96)02630-9. Eur J Obstet Gynecol Reprod Biol. 1997. PMID: 9138962 Review.
Cited by
-
Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation.J Biol Chem. 2010 May 14;285(20):15076-15087. doi: 10.1074/jbc.M109.078915. Epub 2010 Mar 8. J Biol Chem. 2010. PMID: 20212043 Free PMC article.
-
EGFR/HER-targeted therapeutics in ovarian cancer.Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Future Med Chem. 2012. PMID: 22416774 Free PMC article. Review.
-
Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.Cancer Immunol Immunother. 2009 May;58(5):759-67. doi: 10.1007/s00262-008-0599-x. Epub 2008 Oct 3. Cancer Immunol Immunother. 2009. PMID: 18836716 Free PMC article.
-
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.J Exp Med. 1995 Jun 1;181(6):2109-17. doi: 10.1084/jem.181.6.2109. J Exp Med. 1995. PMID: 7539040 Free PMC article.
-
Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.Am J Pathol. 1993 Mar;142(3):733-41. Am J Pathol. 1993. PMID: 8096121 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous